Evidence map›Paper›PMID 41235110›Full record

ArticleFrontiers in pharmacology2025

CEST MRI detects antiretroviral drug toxicities in the developing mouse brain.

Micah Summerlin, Mariano G Uberti, Dhananjay Shinde, Emma G Foster, Brady Sillman, Manjeet Kumar, Baojin Yao, Dongming Peng, Benson J Edagwa, Howard E Gendelman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Micah SummerlinDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Mariano G UbertiDepartment of Radiology, University of Nebraska Medical Center, Omaha, NE, United States.
Dhananjay ShindeDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.
Emma G FosterDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Brady SillmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Manjeet KumarDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Baojin YaoDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Dongming PengDepartment of Electrical and Computer Engineering, University of Nebraska - Lincoln, Lincoln, NE, United States.
Benson J EdagwaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Yutong LiuDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Aditya N BadeDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.

Funding

Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9M
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic InterventionR01HD115482 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade · 2024 to 2026
$1.7M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
Imaging Biomarker for Determining Antiretroviral-induced Neurodevelopmental ImpairmentsR21HD117691 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BADE, ADITYA N, LIU, YUTONG · 2025 to 2025
$422k
NICHD NIH HHS R01 HD115482NICHD NIH HHS R21 HD117691NIMH NIH HHS R01 MH121402NINDS NIH HHS R01 NS034239NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Advances in antiretroviral drugs (ARVs) have achieved remarkable success in preventing gestational human immunodeficiency virus type 1 (HIV-1) transmission from mother to fetus. This is reflected in the rising numbers of HIV-1-exposed uninfected (HEU) children. Worldwide, the number of HEU children exceeds sixteen million, with more than one million children joining this group each year. Although HEU children remain uninfected, they are at an increased risk of neurodevelopmental deficits. Notably,

Indexed as

CEST MRIdolutegravirHIV-1long-acting antiretroviral formulationneurodevelopment

Identifiers

PMID41235110
PMCPMC12605090

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.